Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Skeletal Targeted Radiotherapy: Phase I/II data; Phase II

In NERX’s Phase I/II trial, 18 of 40 evaluable

Read the full 91 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE